MovDisordV3, Main, Exploration, bibRecord, 005E18

Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line

Identifieur interne : 005E18 ( Main/Exploration ); précédent : 005E17; suivant : 005E19

Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line

Auteurs : Beatriz Pardo [Espagne] ; María Angeles Mena [Espagne] ; Stanley Fahn [États-Unis] ; Justo García De Yébenes [Espagne]

Source :

Movement Disorders [ 0885-3185 ] ; 1993.

RBID : ISTEX:1FF422FA48EF46CEFE7C67CC412825F1778A4098

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Ascorbique acide, Culture cellulaire, Dopa, Homme, Neuroblastome, Prévention, Toxicité, Tumeur.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Ascorbic Acid (pharmacology), Ascorbic acid, Brain (metabolism), Brain (pathology), Brain Neoplasms (metabolism), Brain Neoplasms (pathology), Catecholamines (metabolism), Cell Line, Cell culture, Dopa, Drug Interactions, Female, Human, Humans, Levodopa, Levodopa (toxicity), Male, Neuroblastoma, Neuroblastoma (metabolism), Neuroblastoma (pathology), Neuroblastoma cell, Neurotoxicity, Parkinson Disease (drug therapy), Prevention, Quinones (metabolism), Selegiline (pharmacology), Toxicity, Tumor.
MESH :
- chemical , metabolism : Catecholamines, Quinones.
- chemical , pharmacology : Ascorbic Acid, Selegiline.
- drug therapy : Parkinson Disease.
- metabolism : Brain, Brain Neoplasms, Neuroblastoma.
- pathology : Brain, Brain Neoplasms, Neuroblastoma.
- chemical , toxicity : Levodopa.
- Cell Line, Drug Interactions, Female, Humans, Male.

Abstract

Levodopa, at concentrations of 0.25 × 10−4 M or larger, is toxic for the human neuroblastoma cell NB69. Toxicity is associated with high levels of quinones, increased activity of complex II‐III, and lack of changes of complex I of the mitochondrial respiratory chain. Deprenyl, which does not alter the production of quinones, has a partial protective effect. Tocopherol, 23 or 115 × 10−6 M, lacks significant preventive effect on levodopa toxicity, but ascorbic acid, 10−3 M, prevents levodopa toxicity and quinone formation. Deprenyl, 10−4 M, provides additional protection in cultures treated with levodopa and ascorbic acid. Our results indicate that ascorbic acid and deprenyl prevent levodopa neurotoxicity by unrelated mechanisms. Both compounds should be considered as complementary drugs to test for slowing the progression of Parkinson's disease.

Url:

https://api.istex.fr/document/1FF422FA48EF46CEFE7C67CC412825F1778A4098/fulltext/pdf

DOI: 10.1002/mds.870080305

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line</title>
<author><name sortKey="Pardo, Beatriz" sort="Pardo, Beatriz" uniqKey="Pardo B" first="Beatriz" last="Pardo">Beatriz Pardo</name>
</author>
<author><name sortKey="Mena, Maria Angeles" sort="Mena, Maria Angeles" uniqKey="Mena M" first="María Angeles" last="Mena">María Angeles Mena</name>
</author>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
</author>
<author><name sortKey="De Yebenes, Justo Garcia" sort="De Yebenes, Justo Garcia" uniqKey="De Yebenes J" first="Justo García" last="De Yébenes">Justo García De Yébenes</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1FF422FA48EF46CEFE7C67CC412825F1778A4098</idno>
<date when="1993" year="1993">1993</date>
<idno type="doi">10.1002/mds.870080305</idno>
<idno type="url">https://api.istex.fr/document/1FF422FA48EF46CEFE7C67CC412825F1778A4098/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F75</idno>
<idno type="wicri:Area/Istex/Curation">001F75</idno>
<idno type="wicri:Area/Istex/Checkpoint">004085</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Pardo B:ascorbic:acid:protects</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8341291</idno>
<idno type="wicri:Area/PubMed/Corpus">004C19</idno>
<idno type="wicri:Area/PubMed/Curation">004C19</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004C85</idno>
<idno type="wicri:Area/Ncbi/Merge">004955</idno>
<idno type="wicri:Area/Ncbi/Curation">004955</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004955</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Pardo B:ascorbic:acid:protects</idno>
<idno type="wicri:Area/Main/Merge">009057</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:93-0595131</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003717</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003107</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003753</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Pardo B:ascorbic:acid:protects</idno>
<idno type="wicri:Area/Main/Merge">009173</idno>
<idno type="wicri:Area/Main/Curation">005E18</idno>
<idno type="wicri:Area/Main/Exploration">005E18</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line</title>
<author><name sortKey="Pardo, Beatriz" sort="Pardo, Beatriz" uniqKey="Pardo B" first="Beatriz" last="Pardo">Beatriz Pardo</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Research, Centro “Ramón y Cajal,” Madrid</wicri:regionArea>
<wicri:noRegion>” Madrid</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mena, Maria Angeles" sort="Mena, Maria Angeles" uniqKey="Mena M" first="María Angeles" last="Mena">María Angeles Mena</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Research, Centro “Ramón y Cajal,” Madrid</wicri:regionArea>
<wicri:noRegion>” Madrid</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Columbia University College of Physicians & Surgeons, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Yebenes, Justo Garcia" sort="De Yebenes, Justo Garcia" uniqKey="De Yebenes J" first="Justo García" last="De Yébenes">Justo García De Yébenes</name>
<affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">Espagne</country>
<wicri:regionArea>Department of Neurology, Fundación Jiménez Díaz, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1993">1993</date>
<biblScope unit="vol">8</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="278">278</biblScope>
<biblScope unit="page" to="284">284</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1FF422FA48EF46CEFE7C67CC412825F1778A4098</idno>
<idno type="DOI">10.1002/mds.870080305</idno>
<idno type="ArticleID">MDS870080305</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Ascorbic Acid (pharmacology)</term>
<term>Ascorbic acid</term>
<term>Brain (metabolism)</term>
<term>Brain (pathology)</term>
<term>Brain Neoplasms (metabolism)</term>
<term>Brain Neoplasms (pathology)</term>
<term>Catecholamines (metabolism)</term>
<term>Cell Line</term>
<term>Cell culture</term>
<term>Dopa</term>
<term>Drug Interactions</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (toxicity)</term>
<term>Male</term>
<term>Neuroblastoma</term>
<term>Neuroblastoma (metabolism)</term>
<term>Neuroblastoma (pathology)</term>
<term>Neuroblastoma cell</term>
<term>Neurotoxicity</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Prevention</term>
<term>Quinones (metabolism)</term>
<term>Selegiline (pharmacology)</term>
<term>Toxicity</term>
<term>Tumor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Catecholamines</term>
<term>Quinones</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Ascorbic Acid</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Brain Neoplasms</term>
<term>Neuroblastoma</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term>
<term>Brain Neoplasms</term>
<term>Neuroblastoma</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line</term>
<term>Drug Interactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Ascorbique acide</term>
<term>Culture cellulaire</term>
<term>Dopa</term>
<term>Homme</term>
<term>Neuroblastome</term>
<term>Prévention</term>
<term>Toxicité</term>
<term>Tumeur</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa, at concentrations of 0.25 × 10−4 M or larger, is toxic for the human neuroblastoma cell NB69. Toxicity is associated with high levels of quinones, increased activity of complex II‐III, and lack of changes of complex I of the mitochondrial respiratory chain. Deprenyl, which does not alter the production of quinones, has a partial protective effect. Tocopherol, 23 or 115 × 10−6 M, lacks significant preventive effect on levodopa toxicity, but ascorbic acid, 10−3 M, prevents levodopa toxicity and quinone formation. Deprenyl, 10−4 M, provides additional protection in cultures treated with levodopa and ascorbic acid. Our results indicate that ascorbic acid and deprenyl prevent levodopa neurotoxicity by unrelated mechanisms. Both compounds should be considered as complementary drugs to test for slowing the progression of Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Espagne</li>
<li>États-Unis</li>
</country>
<region><li>Communauté de Madrid</li>
<li>État de New York</li>
</region>
<settlement><li>Madrid</li>
</settlement>
</list>
<tree><country name="Espagne"><noRegion><name sortKey="Pardo, Beatriz" sort="Pardo, Beatriz" uniqKey="Pardo B" first="Beatriz" last="Pardo">Beatriz Pardo</name>
</noRegion>
<name sortKey="De Yebenes, Justo Garcia" sort="De Yebenes, Justo Garcia" uniqKey="De Yebenes J" first="Justo García" last="De Yébenes">Justo García De Yébenes</name>
<name sortKey="Mena, Maria Angeles" sort="Mena, Maria Angeles" uniqKey="Mena M" first="María Angeles" last="Mena">María Angeles Mena</name>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005E18 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005E18 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1FF422FA48EF46CEFE7C67CC412825F1778A4098
   |texte=   Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line

Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.